Evolent announces Q2 2026 results and 2027 guidance
Evolent Health reported a 47% increase in Q2 2026 revenue driven by new oncology partnerships, while forecasting 2027 revenue growth of over 25% and adjusted EBITDA margins exceeding $150 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day